Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_3
1
33%
Ph phase_4
1
33%
Ph phase_2
1
33%

Phase Distribution

0

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Other(3)

Detailed Status

unknown3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 21 (33.3%)
Phase 31 (33.3%)
Phase 41 (33.3%)

Trials by Status

unknown3100%

Recent Activity

0 active trials
Showing 3 of 3
unknownphase_2

Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC

NCT04157140
unknownphase_3

TACE+RFA Versus Re-resection for Recurrent Small Hepatocellular Carcinoma

NCT01833286
unknownphase_4

Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Radiofrequency Ablation Alone for Recurrent Hepatocellular Carcinoma

NCT01415063

Clinical Trials (3)

Showing 3 of 3 trials
NCT04157140Phase 2

Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC

Unknown
NCT01833286Phase 3

TACE+RFA Versus Re-resection for Recurrent Small Hepatocellular Carcinoma

Unknown
NCT01415063Phase 4

Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Radiofrequency Ablation Alone for Recurrent Hepatocellular Carcinoma

Unknown

All 3 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
3